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Abstract
The aim of the study was to evaluate the risk factors and the incidence of comorbidity in patients with coronary heart disease, 
depending on the presence of atrial fibrillation.
Materials and methods of research: a retrospective analysis of 222 histories of illnesses of patients with coronary heart dis-
ease who undergo inpatient treatment, aged from 39 to 88 years, has been conducted. Depending on the presence of atrial fibrillation, 
all patients were divided into 2 groups: group 1 (main) – patients with ischemic heart disease with atrial fibrillation (n=105), group 2 
(comparison) – patients with ischemic heart disease without atrial fibrillation (n=117).
Results. In the group of patients without AF, the proportion of persons with inherited exacerbations of IHD was 64.29 %, 
while in the main group – 25.0 %, the differences did not reach the statistically significant level, but this relationship is confirmed by 
the results of the rank correlation analysis – between the presence AP and heredity revealed a significant weak feedback – c=–0.21 
(p<0.05). The diseases that were observed in the examined patients with coronary artery disease present acute stroke, angina pec-
toris, acute myocardial infarction, hypertension, diabetes, pathology of the kidneys and the thyroid gland, diastolic dysfunction 
and obesity. The groups differed in the proportion of patients with stroke – in the group with AF, it was significantly (p=0.002) 
higher – 23.81 %, in compare to 8.55 % in the comparison group.
Conclusions: The presence of atrial fibrillation in patients with coronary heart disease is associated with a high degree of 
comorbidity. First of all, with the combination of IHD and atrial fibrillation, a high incidence of hypertension, diabetes mellitus, 
obesity, acute stroke, kidney disease and thyroid gland is established.
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1. Introduction
At present, atrial fibrillation (AF) is one of the most common forms of arrhythmias, which 
often leads to acute cerebrovascular disruption and has a negative social significance [1, 2].
According to statistics, every fifth case of stroke is due to the presence of atrial fibrillation 
[3, 4]. In this case, ischemic strokes in this type of arrhythmias often have fatal consequences, and 
those surviving patients have consequences with severe disability [5].
It is known, that spread of comorbidity is connected with age [6]. According to literature, 
with age, the prevalence of atrial fibrillation is also increasing: almost 10 % of people over the age of 
80 undergo AF; for those who have reached the age of 94 this figure is up to 25 % [7, 8]. The study of 
risk factors and comorbidity in patients with atrial fibrillation of non-valvular genesis requires a detailed 
analysis, since it has clinical significance for the prevention and treatment of this category of patients.
2. Aim of the research 
To evaluate the risk factors and the incidence of comorbidity in patients with ischemic heart 
disease, depending on the presence of atrial fibrillation.
3. Materials and methods of the research
A retrospective analysis of 222 histories of illnesses of patients with ischemic heart disease 
(IHD) undergoing in-patient treatment on the basis of the “Regional Clinical Hospital named after 
І. І. Mechnikov” during 2015–2016, aged from 39 to 88 years.
Depending on the presence of atrial fibrillation, all patients were divided into 2 groups:
Group 1 (main) – patients with ischemic heart disease with atrial fibrillation (n=105).
Group 2 (comparison) – patients with ischemic heart disease without atrial fibrillation (n=117).
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From all patients were collected anamnestic data, physical and laboratory-instrumental tests 
(clinical and biochemical blood tests, general urine analysis, electrocardiogram registration, radi-
ography of the chest, ultrasound examination of the abdominal cavity). All patients were measured 
anthropometric data with the calculation of the body mass index (BMI) according to the standard 
formula [9]. To evaluate the function of the kidneys were performed the determination of creatinine 
and the calculation of glomerular filtration rate (GFR) according to the MDRD formula [10] accord-
ing to the recommendations of the American National Federation of Nephrology [5, 10]. In order to 
evaluate the hemodynamic parameters, patients underwent pre-pleural cardiac examination of the 
heart using the standard method [9]. In the presence of indications, the patient was monitored with 
the Holter’s method. The functional state of the thyroid gland was determined by the evaluation of 
thyroid hormones with the subsequent consultation of the endocrinologist.
For statistical processing of the research material, the following biostatistical methods were 
used: verification of the normality of the distribution of quantitative attributes in separate groups 
of comparison by the Shapiro-Wilka criterion; estimation of the reliability of the mean difference 
for quantitative signs with abnormal distribution by the Mann-Whitney criterion (U); correlation 
analysis with calculation of Spearman rank correlation coefficients (ρ). To describe the selective 
abnormal distribution of quantitative signs, the median (Me) and the interquartile scale (25 %, 
75 %) were used. For the calculated relative values (P), the average error of the relative magnitude 
(mR) and 95 % confidence intervals were determined by the Wilson method with the correction for 
continuity. For the analysis of the relationships between different features, a correlation analysis 
was used to calculate the Spirman rank correlation coefficients (ρ) [11].
The critical value of the statistical significance level when checking the null hypotheses was 
taken as 0.05 (5 %). When the value of p>0.05 was obtained, the difference between the indices was 
considered to be unreliable [12].
Statistical processing of the results was performed using the STATISTICA 6.1 software 
(StatSoftInc., Serial number AGAR909E415822FA), Excel 2010, and the MedCalcStatistical Soft-
ware trial version 17.4 software package. (MedCalcSoftwarebvba, Ostend, Belgium).
4. Results of the research
The general characteristics of the study groups are shown in Table 1.
Since the abnormal distribution of quantitative signs was observed in the overwhelming 
majority (over 80 %) of indicators for describing the central trend of data, the median and the inter-
quartile Me (25 %, 75 %) were used.
Analysis on the homogeneity of the study groups showed that there were no significant 
differences in the distribution of patients in groups depending on sex, anthropometric indicators 
(average height, weight, BMI), risk factors (heredity, smoking) (p>0.05), indicating their compara-
bility and allows comparisons of other parameters.
The presence of statistically significant differences according to age characteristics was 
determined (p<0.001): in the group with AF, on average, older patients (average age 65.0 (59.0; 
72.0)) compared with the group without AF (60.0 (53.0; 69.0)). The proportion of persons over the 
age of 60 in the main group is 68.57 %, in the comparison group – 48.72 % (p=0.003). The inverse 
weak link between the presence of AF (group) and age is the Spearman correlation coefficient 
c=–0.23 (p<0.05). 
The proportion of persons with BMI greater than 30 is higher in the group without atrial 
fibrillation (36.46 % versus 27.27 % in the AF group) without statistically significant differences.
In the group of patients without AF, the proportion of persons with inherited exacerba-
tions of IHD was 64.29 %, while in the main group – 25.0 %, the differences did not reach the 
statistically significant level, but this relationship is confirmed by the results of the rank correla-
tion analysis – between the presence AF and heredity revealed a significant weak feedback – 
c=–0.21 (p<0.05).
The diseases observed in the examined patients with ischemic heart disease are acute stroke, 
angina pectoris, acute coronary syndrom (ACS), hypertension (HT), diabetes mellitus (DM), kidney 
and thyroid pathology, diastolic dysfunction (DD) and obesity (Table 2).
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Table 1
The general characteristics of the study groups with IHD
Indicators Totally observed Group with AF Group without AF р
Number 222 (100.0 %) 105 (47.3 %) 117 (52.7 %) –
Sex, n ( %)
man 55 (52.38 %) 59 (50.43 %) 59 (50.43 %)
0.771*
female 50 (47.62 %) 58 (49.57 %) 58 (49.57 %)
Age
Min – max 39.0–88.0 42.0–88.0 39.0 – 84.0 –
Average age Ме (25 %; 75 %) 64.0 (55.0; 70.0) 65.0 (59.0; 72.0) 60.0 (53.0; 69.0) <0.001#
Structure by age, n ( %)
Age<60 years 93 (41.89 %) 33 (31.43 %) 60 (51.28 %)
0.003*
Age>60 years 129 (58.11 %) 72 (68.57 %) 57 (48.72 %)
Anthropometric indicators, Ме (25 %; 75 %)
Height (cm) 170.0 (162.0; 178.0) 170.0 (160.0; 180.0) 168.0 (163.0; 176,0) 0.446#
Weight (kg) 82.0 (70.0; 97.0) 81.0 (70.0; 95.0) 82.5 (72.0; 98.0) 0.492#
BMI
Min – max 19.53–47.9 19.53–42.2 20.4–47.9 –
Average BMI Ме  
(25 %; 75 %)
29.05 (23.88; 33.31) 28.55 (23.44; 32.05) 29.48 (24.79; 34.40) 0.146#
BMI>30, n ( %) 53 (23.87 %) 18 (17.14 %) 35 (29.91 %) 0.026*
Risk factors, n (%)
n (data available) 26 12 14
Heredity (data available) 12 (46.15 %) 3 (25.0 %) 9 (64.29 %) 0.053**
Heredity (observed) 12 (5.41 %) 3 (2.86 %) 9 (7.69 %) 0.097**
n(data available) 20 8 12
Smoking (data available) 10 (4.5 %) 2 (1.9 %) 8 (6.84 %) 0.072**
Smoking (observed) 10 (4.5 %) 2 (1.9 %) 8 (6.84 %) 0.077**
Note: p – differences between groups; # – for quantitative attributes according to the Mann-Whitney criterion; * – for qualitative 
characteristics according to criterion χ2 of Pearson; ** – for qualitative signs according to Fischer’s exact criterion
The groups differed in the proportion of patients with acute stroke – in the group with AF, 
it was significantly (p=0.002) higher – 23.81 %, compared with 8.55 % in the comparison group. 
Also, the differences were determined by angina – in the group without AF, the proportion of pa-
tients with coronary artery disease was higher and amounted to 58.97 %, whereas among patients 
with atrial fibrillation – 31.43 % (p<0.001). The difference is mainly due to discrepancies in the 
presence of angina of the 3rd functional class – 38.46 % in the group without AF and 20.95 % in 
the presence of atrial fibrillation (p=0.005). 
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Table 2
Comorbidity in patients with ischemic heart disease, n (%)
Disease Totally observed (n=222)
Group with AF 
(n=105)
Group without AF 
(n=1117) р*
1 2 3 4 5
Acute stroke, n (%)
without acute stroke 187 (84.23 %) 80 (76.19 %) 107 (91.45 %)
0.002
with acute stroke 35 (15.77 %) 25 (23.81 %) 10 (8.55 %)
ACS, n (%)
without ACS 176 (79.28 %) 87 (82.86 %) 89 (76.07 %)
0.213
with ACS 46 (20.72 %) 18 (17.14 %) 28 (23.93 %)
Angina pectoris, n (%)
without angina pectoris 120 (54.05 %) 72 (68.57 %) 48 (41.03 %)
<0.001
with angina pectoris 102 (45.95 %) 33 (31.43 %) 69 (58.97 %)
Functional class of angina pectoris, n (%)
2 29 (13.06 %) 11 (10.48 %) 18 (15.38 %) 0.279
3 67 (30.18 %) 22 (20.95 %) 45 (38.46 %) 0.005
4 2 (0.9 %) 0 (0 %) 2 (1.71 %) 0.534
Hypertension (HT), n (%)
without hypertension 24 (10.81 %) 15 (14.29 %) 9 (7.69 %)
0.114
with hypertension 198 (89.19 %) 90 (85.71 %) 108 (92.31 %)
Degree of HT, n (%)
2 131 (59.01 %) 59 (56.19 %) 72 (61.54 %) 0.419
3 67 (30.18 %) 31 (29.52 %) 36 (30.77 %) 0.883
Stage of HT, n (%)
1 11 (4.95 %) 8 (7.62 %) 3 (2.56 %) 0.083
2 118 (53.15 %) 57 (54.29 %) 61 (52.14 %) 0.749
3 70 (31.53 %) 25 (23.81 %) 45 (38.46 %) 0.019
Diabetes mellitus (DM), n (%)
n 211 102 109
without DM 124 (58.77 %) 62 (60.78 %) 62 (56.88 %)
0.564
with DM 87 (41.23 %) 40 (39.22 %) 47 (43.12 %)
Decrease of GFR, n (%)
n 181 79 102
without pathology 54 (29.83 %) 21 (26.58 %) 33 (32.35 %)
0.400
with pathology 127 (70.17 %) 58 (73.42 %) 69 (67.65 %)
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1 2 3 4 5
Hypo- or hyperthyroidism, n (%)
n 181 75 106
without pathology 86 (47.51 %) 29 (38.67 %) 57 (53.77 %)
0.045
with pathology 95 (52.49 %) 46 (61.33 %) 49 (46.23 %)
Obesity, n (%)
n 166 67 99
without obesity 90 (54.22 %) 39 (58.21 %) 51 (51.52 %)
0.396
with obesity 76 (45.78 %) 28 (41.79 %) 48 (48.48 %)
Stage of obesity, n (%) 
0 90 (54.22 %) 39 (58.21 %) 51 (51.52 %) 0.396
1 45 (27.11 %) 20 (29.85 %) 25 (25.25 %) 0.711
2 21 (12.65 %) 4 (5.97 %) 17 (17.17 %) 0.002
3 9 (5.42 %) 4 (5.97 %) 5 (5.05 %) 0.730
4 1 (0.6 %) 0 (0 %) 1 (1.01 %) 0.323
Diastolic disfunction (Е/А˂1), n (%)
n 143 40 103
without DD 62 (43.36 %) 31 (77.5 %) 31 (30.1 %)
<0.001
with DD 81 (56.64 %) 9 (22.5 %) 72 (69.9 %)
Note: * – p is the difference between the groups according to Pearson’s criterion χ2, including the Yeats correction
Patients with atrial fibrillation did not differ in the proportion of people with acute myo-
cardial infarction – in general, 20.72 % with a minor excess in the comparison group (23.93 % vs. 
17.14 %), hypertension (92.31 % in the group without AF, and 85.71 % in the AF group), diabetes 
mellitus (43.12 % and 39.22 % respectively), kidney pathology (67.65 % and 73.42 % respectively), 
obesity (48.48 % and 41.79 % % respectively).
In the structure of the distribution according to the HT stage, there were no discrepancies 
regarding the stage of the disease, and then differences were observed only in the proportion of pa-
tients with 3rd stage HT, which was higher in the comparison group (38.46 % in the group without 
AF with 23.81 % with atrial fibrillation).
It should be noted that there are significant differences (p=0.002) between the groups in the 
proportion of patients with obesity of the 2nd stage – the proportion of such patients is greater in 
the group without AF (5.97 %), compared with the group with AF (17.17 %).
The proportion of patients with diastolic dysfunction (DD) in the group without AF is sig-
nificantly higher (69.9 %) compared with the group without AF – 22.5 % (p<0.001).
Thyroid dysfunction was found in the main group with a frequency of 61.33 % (95 % CI 
50.02–71.54), which is statistically significant (p<0.05) and can be compared more with the group 
without AF – 46.23 % (95 % CI 37.03–55.68). In addition to the thyroid pathology, in the main 
group, the frequency of GPMC was significantly higher (p<0.05), significantly lower – the frequen-
cy of angina and DD (Fig. 1).
Continuation of Table 2
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In the main study group, the incidence of concomitant pathology in the order of decline pre-
dominated: HT, kidney pathology and thyroid pathology; whereas in the comparison group – HT, 
diastolic dysfunction and kidney pathology. The last ranked place in the frequency of occurrence 
in the group with AF was acute myocardial infarction – 17.14 % (95 % CI 11.13-25.48), while in the 
comparison group, the penultimate one with a frequency of 23.93 % (95 % CI 17, 11–32.41).
By rank correlation analysis, reliable (p<0.05) inverse correlation bonds of mean strength 
of AF with diastolic dysfunction (ρ=–0.43; p<0.001) were found; weak – with angina pectoris (ρ= 
=–0.28; p<0.001) and degree of GC (ρ=–0.20; p=0.003). Consequently, in the presence of these dis-
eases, atrial fibrillation develops less frequently. Direct weak correlations were detected between 
AF and acute stroke (ρ=0.21; p=0.002) and pathology of the thyroid gland (ρ=0.15; p=0.045), there-
fore, atrial fibrillation develops more frequently in these pathologies.
Fig. 1. Comorbidity in the examined patients with coronary artery disease, depending on  
the presence of atrial fibrillation (P±mr, %): * – p<0.05 compared with the group without AF by 
the Pearson χ2 criterion
5. Discussion
According to the results of numerous studies with age, increases the incidence of cardiovas-
cular diseases such as hypertension, ischemic heart disease, heart failure, various cardiac arrhyth-
mias, post-infarction cardiosclerosis [13, 15].
The results of the study are consistent with the literature, which indicates that the presence 
of atrial fibrillation also increases with age [15, 16]. At the same time, according to modern ideas 
and results obtained, the incidence of atrial fibrillation and the frequency of comorbidity [17] in-
creases with age, which greatly complicates the diagnosis and choice of therapeutic tactics when 
combined with a patient with comorbidity and atrial fibrillation [18].
Nowadays, there are data on the relationship between body mass and the development of 
cardiovascular disease [19]. Some studies indicate that patients with high body weight have lower 
mortality in patients with heart failure than patients with low body weight [9, 20]. According to the 
European guidelines, in the presence of atrial fibrillation, the mass of the body may be a predictor 
of its development [7, 21], which does not contradict the results. According to the study, the inci-
dence rate of obesity was found to be rather high in both groups.
Identification at an early stage the diagnosis, the patient’s risk factors and comorbid pa-
thology is important for the primary prevention as well as for secondary prevention in order to 
prevent the development of repeated acute stroke, which often develop in this category of patients 
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[22, 23]. Development of individual practical recommendations for the diagnosis and treatment 
of atrial fibrillation in patients with ischemic heart disease, depending on the presence of comor-
bidity pathology [24], which is planned in the future, has a promising value in practice.
6. Conclusions
1. The presence of atrial fibrillation in patients with coronary heart disease is associated 
with a high degree of comorbidity that increases with age.
2. In case of combination IHD and atrial fibrillation was detected a high incidence of 
hypertension, diabetes mellitus, obesity, acute cardiovascular disorders, kidney disease and 
thyroid gland.
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